Clinical Trial Update: A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AL101 in patients with activating Notch mutations in Adenoid Cystic Carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• AL101

Snippet

Sponsor: Ayala Pharmaceuticals, Inc, | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-31